VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GRDNGuardian Pharmacy Services, Inc.
$46.67$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
GRDN logo

Guardian Pharmacy Services, Inc.

GRDN
NYSE · Drug Distributors & Pharmacies
$46.67
At close - Nov 19, 4:00 PM EST - USD
Market Cap$2.96B
P/E39.9x
52W High$50.85
Volume585.25K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Thin Margins Meet Rebuilt Balance Sheet Under Pricing Pressure

GRDN has rebuilt its equity base from $17.9M in Q2 2024 to $267.2M in Q3 2026 and reduced its debt-to-equity ratio to 0.13, suggesting a deliberate deleveraging supported by retained earnings growth.

GrowthMixed
ProfitabilityModerate
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

GRDN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

+51% Peers

P/E is 51% above peer median

03

Market leadership

RS 93 · Leader

High momentum (Outperforming 93% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
GRDN+58.04%
S&P 500 (^GSPC)+4.79%
1-Year Return
GRDN+69.40%
S&P 500 (^GSPC)+8.03%
3-Year Return
GRDN+191.69%
S&P 500 (^GSPC)+48.89%
5-Year Return
GRDN+191.69%
S&P 500 (^GSPC)+44.90%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
39.9x
Forward P/EExpansion
35.8x
EV/EBITDA100th %ile
23.7x
FCF YieldCash Flow
3.3%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
39.9x
38.6x
100th· High
EV/EBITDA
23.7x
16.9x
100th· High
Price/FCF
30.7x
30.2x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$14.60-68.7%
Base (Fair)$26.66-46.2%
Bull$38.07-18.4%
$14.60 Bear$26.66 Base$38.07 Bull
Current Market Price: $46.67
Trades at a 75.1% premium to Base DCF ($26.66)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.45B+17.9% YoY
Net income FY25
$49M+156.4% YoY
Free cash flow FY25
$81M+94.1% YoY
Operating margin FY25
6.1%+11.3 pts YoY
ROIC (FY25)36.6%
Avg ROIC 5Y16.7%
ROE (TTM)30.3%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (78%)
Revenue Beat Rate7/12 (78%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.33+4.9%
vs $0.31
$371M+1.5%
vs $366M
Q3 2026
Aug 6, 2026
$0.29+10.8%
vs $0.26
$352M+3.3%
vs $340M
Q2 2026
May 6, 2026
$0.29+20.8%
vs $0.24
$337M+2.0%
vs $330M
Q2 2026
Mar 11, 2026
$0.37+37.0%
vs $0.27
$398M+1.9%
vs $390M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·Nov 10, 2026
NBIX or GRDN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research·Nov 9, 2026
NBIX vs. GRDN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those looking for undervalued stocks?

MarketBeat·Nov 7, 2026
What Guardian Pharmacy Services (GRDN) Said on Its Q3 Earnings Call

Guardian Pharmacy Services NYSE: GRDN raised its full-year revenue and adjusted EBITDA guidance after third-quarter profit rose on higher prescription volumes, improved reimbursement and purchasing initiatives, even as drug price reductions weighed on reported revenue.

Seeking Alpha·Nov 6, 2026
Guardian Pharmacy Services, Inc. (GRDN) Q3 2026 Earnings Call Transcript

Guardian Pharmacy Services, Inc. ( GRDN ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ashley Stockton - Head of Investor Relations & Senior Director Fred Burke - CEO, President & Director David Morris Will Mudd - Senior VP & CFO Conference Call Participants Brian Tanquilut - Jefferies LLC, Research Division Zachary Haggerty - KeyBanc Capital Markets Inc., Research Division Raj Kumar - Stephens Inc., Research Division David MacDonald - Truist Securities, Inc., Research Division Parker Snure - Raymond James & Associates, Inc., Research Division Allen Lutz - BofA Securities, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to Guardian Pharmacy's Third Quarter 2026 Earnings Call.

Filtered for Guardian Pharmacy Services, Inc.More Headlines
04

Compare before deciding

Benchmark GRDN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Guardian Pharmacy Services, Inc. (GRDN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
GRDN logoGRDNGuardian Pharmacy Services, Inc.Current
$46.67$2.96B39.9017.93%5.13%30.28%—
OMCL logoOMCLOmnicell, Inc.
$33.18$1.51B34.526.53%3.59%3.5%—
CVS logoCVSCVS Health Corp.
$80.04$102.13B9.357.85%2.63%14.1%3.34%
MCK logoMCKMcKesson Corporation
$1062.16$123.95B26.3712.36%1.12%—0.29%
CAH logoCAHCardinal Health, Inc.
$272.34$63.78B34.9014.23%0.71%—0.76%
VEEV logoVEEVVeeva Systems Inc.
$262.92$42.71B42.7716.34%29.34%14%—

Compare GRDN vs Peers

Guardian Pharmacy Services, Inc. (GRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs OMCL

Most directly comparable listed peer for GRDN.

Scale Benchmark

vs MCK

Larger-name benchmark to compare GRDN against a more recognizable public peer.

Peer Set

Compare Top 5

vs OMCL, CVS, MCK, CAH

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

GRDN SEC Filings & Documents

Guardian Pharmacy Services, Inc. (GRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

Jun 22, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 11, 2026·SEC

FY 2025

Mar 26, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when GRDN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

GRDN Frequently Asked Questions

Guardian Pharmacy Services, Inc. (GRDN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Guardian Pharmacy Services, Inc.'s revenue?

Guardian Pharmacy Services, Inc. (GRDN) reported $1.46B in revenue over the trailing twelve months. Revenue was $1.45B in fiscal year 2025. That is 141% more than the $600.4M of fiscal year 2018.

How fast is Guardian Pharmacy Services, Inc. growing?

Guardian Pharmacy Services, Inc. (GRDN) grew revenue by 4.9% over the trailing twelve months, compared with the twelve months before.

Is GRDN profitable?

Yes. Guardian Pharmacy Services, Inc. (GRDN) earned $74.8M in net income over the trailing twelve months (a 5.1% net margin).

Dividend & Returns
What is GRDN's return on equity?

Guardian Pharmacy Services, Inc. (GRDN) had a return on equity (ROE) of 30.3% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Guardian Pharmacy Services, Inc.'s free cash flow?

Guardian Pharmacy Services, Inc. (GRDN) generated $96.2M in free cash flow over the trailing twelve months.

What if you invested $1,000 in GRDN back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →